A small commuter town surrounded by sugarcane fields in southeastern Brazil, one of the countries hardest hit by COVID-19, has shown that even a vaccine that had low efficacy in some clinical trials can dramatically control the pandemic virus.
As part of an unusual experiment to track the real-world effectiveness of CoronaVac, a COVID-19 vaccine made by a Chinese company, almost all adult residents of Serrana, in the state of São Paulo, received the required two shots between February and April, long before most would otherwise have become eligible for the vaccine. The results were dramatic. Symptomatic cases of COVID-19 have dropped by 80% since the start of mass vaccination, related hospitalizations fell 86%, and deaths plummeted 95%, the research team in charge of the experiment reported during a press conference yesterday.
Read the full article here.
Refana Inc., is United States registered private corporation dedicated to finding practical and innovative solutions to the world's medical problems. By utilizing a highly collaborative open source system of research and development Refana has been able to attract world leaders in their respective scientific and medical fields to work on these problems. Through this model Refana hopes to greatly accelerate the vaccine development process for Covid-19 and help protect not only the health of the world, but also the economies and stability of nations at risk.